Endocrinology, Department of Health Sciences, University Magna Graecia of Catanzaro, 88100 Catanzaro, Italy.
School of Human and Social Sciences, University Kore of Enna, via della Cooperazione, 94100 Enna, Italy.
Endocr Rev. 2017 Oct 1;38(5):379-431. doi: 10.1210/er.2017-00073.
The insulin receptor (IR) gene undergoes differential splicing that generates two IR isoforms, IR-A and IR-B. The physiological roles of IR isoforms are incompletely understood and appear to be determined by their different binding affinities for insulin-like growth factors (IGFs), particularly for IGF-2. Predominant roles of IR-A in prenatal growth and development and of IR-B in metabolic regulation are well established. However, emerging evidence indicates that the differential expression of IR isoforms may also help explain the diversification of insulin and IGF signaling and actions in various organs and tissues by involving not only different ligand-binding affinities but also different membrane partitioning and trafficking and possibly different abilities to interact with a variety of molecular partners. Of note, dysregulation of the IR-A/IR-B ratio is associated with insulin resistance, aging, and increased proliferative activity of normal and neoplastic tissues and appears to sustain detrimental effects. This review discusses novel information that has generated remarkable progress in our understanding of the physiology of IR isoforms and their role in disease. We also focus on novel IR ligands and modulators that should now be considered as an important strategy for better and safer treatment of diabetes and cancer and possibly other IR-related diseases.
胰岛素受体(IR)基因经历差异剪接,产生两种 IR 同工型,IR-A 和 IR-B。IR 同工型的生理作用尚未完全阐明,似乎取决于它们对胰岛素样生长因子(IGFs)的不同结合亲和力,特别是对 IGF-2 的亲和力。IR-A 在产前生长和发育中的主要作用和 IR-B 在代谢调节中的主要作用已得到充分证实。然而,新出现的证据表明,IR 同工型的差异表达也可能有助于解释胰岛素和 IGF 信号转导和作用在各种器官和组织中的多样化,这不仅涉及不同的配体结合亲和力,还涉及不同的膜分区和运输,以及可能与各种分子伴侣的不同相互作用能力。值得注意的是,IR-A/IR-B 比值的失调与胰岛素抵抗、衰老以及正常和肿瘤组织增殖活性的增加有关,并且似乎持续存在有害影响。这篇综述讨论了新的信息,这些信息在我们对 IR 同工型的生理学及其在疾病中的作用的理解方面取得了显著进展。我们还重点介绍了新型的 IR 配体和调节剂,这些配体和调节剂现在应该被视为改善和更安全地治疗糖尿病和癌症以及可能的其他与 IR 相关疾病的重要策略。